Bullfrog AI enters collaboration with Eleison to optimize Phase 3 pancreatic cancer trial

BullFrog AI Holdings, Inc.

Collaboration announced Feb 27, 2025; Bullfrog AI to apply bfLEAP platform to Eleison's glufosfamide Phase 3 trial.
Bullfrog Data Networks will analyze safety signals and extract predictive biomarkers from prior and ongoing studies.
Eleison's ongoing glufosfamide Phase 3 trial targets second-line pancreatic cancer; expected completion in 2027.
Financial terms of the agreement were not disclosed.
Partnership also covers Eleison's pipeline programs ILC (lung cancer) and DBD (brain cancers).

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-25-008518
form_type: 8-K
ticker: BFRG
cik: 0001829247
company_name: BullFrog AI Holdings, Inc.
filed_at: 2025-02-27T23:59:59+00:00
discovered_at: 2026-05-14T18:03:05.130831+00:00
generated_at: 2026-05-26T02:32:57.237573+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-25-008518
json_url: https://secwatch.observer/filing/0001493152-25-008518.json
markdown_url: https://secwatch.observer/filing/0001493152-25-008518.md
text_url: https://secwatch.observer/filing/0001493152-25-008518.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1829247/000149315225008518/0001493152-25-008518-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1829247/000149315225008518/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-25-008518

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.